Getting new treatments into the hands of patients is a scientific challenge, and a financial one too. According to a JAMA Network Open study, the average cost to develop a new drug in the U.S. was around $879 million between 2000 and 2018. The same study notes that other research places the R&D cost for a new drug anywhere from $314 million to a staggering $4.46 billion.
That’s where computer simulation software steps in. By modeling complex biological systems, predicting how drugs behave, and simulating clinical trials before they happen, this tech is helping researchers make better decisions.
The usual path of drug discovery and development has many challenges leading to high costs and long timelines. Simulation software flips that equation.
A ScienceDirect review points out that if you can cut R&D and manufacturing costs, you unlock flexibility, which is critical when those two things can make up 60% to 80% of a drug’s price tag. The same review cited a model-based design of experiments (DoE) that cut development time by 72% and reduced material use by 73%. That’s more than just incremental.
Where simulation is making an impact:
Simulating how drugs move through the body (PK) and how they act on the body (PD) helps fine-tune dosing and delivery, making treatments more effective and safer.
Computer simulations use patient-specific inputs to guide precision dosing through PK/PD models.
Source: ResearchGate
Teams can test how different variables affect outcomes: patient response, side effects, even production bottlenecks, before committing to full trials or scale-up.
An Arxiv review discusses how AI-powered models let researchers simulate patient groups and trial scenarios. This approach helps identify issues early and can reduce the need for animal testing.
In silico clinical trial protocol overview.
Source: ResearchGate
Instead of physically testing thousands of compounds, AI-driven simulations can screen digital libraries for likely hits, narrowing the focus and speeding up the early pipeline.
The utility of computer simulation software extends far beyond the pharmaceutical lab, impacting various aspects of medical practice and healthcare delivery.
As this PMC study explains, simulation-based training (SBT) gives medical students and pharmacy trainees hands-on experience, minus the risk. VR, AR, mannequins, and standardized patient simulations help them practice everything from technical procedures to patient conversations.
Teams can rehearse rare or complex scenarios, like cancer surgery complications or emergency airway procedures, so they’re ready when the real scenario happens.
Before a prototype is even built, engineers can simulate how a device will interact with the human body. That means fewer failed designs and better outcomes before launch.
The adoption of computer simulation software requires investment, but the returns can be substantial, impacting both financial and clinical aspects.
For instance, simulations slash the need for physical experiments. This means fewer materials, fewer hours, and faster time-to-market for life-saving drugs or tools. A ResearchGate article explicitly states computer simulation is “economical in terms of time, money and manpower as compared to real laboratory experimentations.”
This efficiency also contributes to lower failure rates by running early-stage scenarios virtually, where researchers can identify potential failures early.
Additionally, simulation leads to better resource use. Hospitals and clinics can use simulation to optimize staffing, predict patient flow, and stress-test systems, all without disrupting actual care.
Selecting the right software is critical. Insights from LinkedIn’s advice page and the FasterCapital blog suggest considering:
Despite the immense potential, the adoption and effective use of computer simulation software comes with certain challenges:
If your input data is off, your simulations will be too. You’ve got to validate your models with real-world results.
High-quality simulation software can be expensive. Their effective use demands staff with specialized skills in modeling and data analysis.
Simulations often require large, high-quality datasets. Integrating data from disparate sources can be complex, as highlighted in Kanda’s article on AI adoption in healthcare.
While simulations are powerful, they are still models of reality. It’s important to remember that real biological systems can exhibit complexities not captured in any model. Even with AI integration, some models may have limitations.
A tangible example of simulation software’s impact is Kanda’s Biosimulation Tool Performing in Silico Experiments. This tool was developed for a leading international manufacturer of pharmaceuticals and laboratory equipment to enhance their bioprocess development. The challenge in commercial antibody production often includes low yields, inhibited growth due to toxins, extensive timelines for cell culture and optimization, and high costs.
Kanda’s solution, Cell Insights, is a cloud-based bioreactor simulation tool that allows scientists and researchers to:
The application blends traditional mathematical models from Chemical Engineering with new ML/AI algorithms. This provides accurate and informative experimental simulations. Key features are an intuitive user interface with a guided workflow, a full list of parameters for model setup and support for users adding custom functions.
Handling the development or integration of advanced simulation software needs special expertise in both software engineering and the medical and pharmaceutical fields. Kanda offers deep experience in:
Talk to our experts to discover how Kanda can help you use computer simulation software to speed up your research, and bring new healthcare solutions to life faster.
Simulation software is already changing how healthcare works. Challenges do exist but ongoing progress in AI and cloud computing is making these tools more available and effective.
By using simulation, the healthcare and pharmaceutical sectors can work through modern science with more accuracy. This leads to better, faster and more cost-effective patient solutions.
